(Q42619217)

English

Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis

scientific article published on December 1, 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis (English)

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

0 references

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

4

object named as

G. Pioli

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773136

20 November 2022

author name string

M. Passeri

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773136

20 November 2022

M. C. Baroni

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773136

20 November 2022

M. Pedrazzoni

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773136

20 November 2022

M. Barbagallo

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773136

20 November 2022

D. Costi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773136

20 November 2022

M. Biondi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773136

20 November 2022

G. Girasole

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773136

20 November 2022

B. Arlunno

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773136

20 November 2022

E. Palummeri

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1773136

20 November 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1773136

20 November 2022

publication date

1 December 1991

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

full work available at URL

https://api.elsevier.com/content/article/PII:016960099190129N?httpAccept=text/xml

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

https://api.elsevier.com/content/article/PII:016960099190129N?httpAccept=text/plain

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Bone and Mineral

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

237-247

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages

4

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages

5

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate.

6

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone

7

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.

8

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro

9

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation

10

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Etidronate disodium in postmenopausal osteoporosis

12

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

13

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study I, osteoporosis trial Hannover

14

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study

15

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study

16

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate

17

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

18

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD

20

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)

21

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Prevention of postmenopausal bone loss by tiludronate

22

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Effect of etidronate disodium on bone turnover following surgical menopause

23

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.

24

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Antiresorptive dose-response relationships across three generations of bisphosphonates

25

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.

26

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy

27

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.

28

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Short-term effects on bone and mineral metabolism of 4-amino-1-hydroxybutylidene-1,1-diphosphonate (ABDP) in Paget's disease of bone

29

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate

30

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

The acute-phase response after bisphosphonate administration

32

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Measurement of pain

33

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study

35

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Low back pain in Paget's disease of bone

37

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Treatment of painful bone lesions and hypercalcemia

38

1 reference

10.1016/0169-6009(91)90129-N

https://api.crossref.org/works/10.1016/0169-6009(91)90129-N

20 November 2022

Identifiers

10.1016/0169-6009(91)90129-N

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42619217&oldid=1775362710"